Pushpita Roy

Magnitude of Survival Benefit Associated With Tyrosine Kinase Inhibitors in Advanced Thyroid Carcinoma: A Systematic Review and Meta-Analysis Incorporating Updated Long-Term Evidence From SELECT (Lenvatinib) and COSMIC-311 (Cabozantinib) Trials

Background: Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced thyroid carcinoma. However, newer agents and updated long-term evidence from pivotal trials have not been comprehensively synthesized. This systematic review and meta-analysis integrates rec...